There is no satisfactory treatment for Huntington's disease (HD), a hereditary neurodegenerative disorder that produces chorea, dementia, and death. One potential treatment strategy involves the replacement of dead neurons by stimulating the proliferation of endogenous neuronal precursors (neurogenesis) and their migration into damaged regions of the brain. Because growth factors are neuroprotective in some settings and can also stimulate neurogenesis, we treated HD transgenic R6͞2 mice from 8 weeks of age until death by s.c. administration of FGF-2. FGF-2 increased the number of proliferating cells in the subventricular zone by Ϸ30% in wild-type mice, and by Ϸ150% in HD transgenic R6͞2 mice. FGF-2 also induced the recruitment of new neurons from the subventricular zone into the neostriatum and cerebral cortex of HD transgenic R6͞2 mice. In the striatum, these neurons were DARPP-32-expressing medium spiny neurons, consistent with the phenotype of neurons lost in HD. FGF-2 was neuroprotective as well, because it blocked cell death induced by mutant expanded Htt in primary striatal cultures. FGF-2 also reduced polyglutamine aggregates, improved motor performance, and extended lifespan by Ϸ20%. We conclude that FGF-2 improves neurological deficits and longevity in a transgenic mouse model of HD, and that its neuroprotective and neuroproliferative effects may contribute to this improvement.
H
untington's disease (HD) is a progressive and fatal neurological disorder caused by a polyglutamine expansion in the N terminus of the protein huntingtin (Htt). Expansions of Ͼ36 glutamines cause the disease. There is currently no treatment to delay the appearance or progression of the disease. HD is characterized by a dramatic loss of neurons in the striatum and cerebral cortex, resulting in chorea, dementia, and early death. Multiple molecular pathways are involved in the pathophysiology of HD. Disease initiation and progression are thought to involve a conformational change in the Htt protein due to the polyglutamine expansion (1), altered protein-protein interactions (2), abnormal protein aggregation (3) and proteolysis, leading to transcriptional dysregulation (4-6), excitotoxicity (7) , and mitochondrial dysfunction (8) , and culminating in extensive loss of neurons in the striatum and cerebral cortex (9) . The precise cause of neuronal cell death and the relative contributions of the various above-mentioned abnormalities to this process are not known.
Possible approaches to the treatment of HD include blocking neuronal dysfunction and death and replacing lost cells. Several growth factors have been implicated in neuroprotection and neurogenesis, suggesting that they might have salutary effects in HD. We chose to investigate FGF-2 for a variety of reasons. FGF-2 knockout (FGF-2 Ϫ/Ϫ ) mice exhibit impaired neurogenesis, suggesting a requirement for FGF-2 in this process (10) . FGF-2 also protects striatal neurons in toxin-induced models of HD (11) , exerts trophic effects on striatal neurons (12) , stimulates proliferation (13) of striatal neural stem cells, and regulates Htt expression by cultured striatal neurons (14) . FGF-2 may also stabilize cellular calcium homeostasis and enhance antioxidant defense systems that are impaired in HD. Finally, FGF-2 can be administered systemically and cross the blood-brain barrier to produce cerebral effects (15, 16) , obviating the requirement for more complex or invasive modes of delivery.
Therefore, we examined whether FGF-2 treatment can reduce neuronal loss, increase neurogenesis, and improve functional outcome in HD transgenic R6͞2 mice, which express exon-1 of Htt with 145 polyglutamine repeats. This is the most extensively characterized genetic model of HD and has a reproducible phenotype manifested by early onset (5-6 weeks) of tremor, irregular gait, and abnormal movements, rapid disease progression, and death at 12-15 weeks (17) . We show that FGF-2 stimulates neurogenesis, induces migration of newborn cells into the striatum and cortex, is neuroprotective in vitro, and significantly extends the lifespan of HD transgenic R6͞2 mice.
Methods
Tissue Culture, Western Blot Analysis, and Immunohistochemistry.
The methods are found in refs. 3, 16, and 17 and Supporting Text, which is published as supporting information on the PNAS web site.
R6͞2 Transgenic and Wild-Type Mice. All animal experiments were performed according to procedures approved by the Institutional Animal Care and Use Committee. Heterozygous Htt exon-1-trangenic mice of strain R6͞2 (145 CAG repeats) were obtained from The Jackson Laboratory. Animals were genotyped by PCR of tail-tip DNA, and CAG repeat size was determined. Wild-type (n ϭ 20) and R6͞2 (n ϭ 20) were separated into equal FGF-2 (Chemicon; GF003) or vehicle (PBS) treatment groups according to ref. 17 . The treatment groups contained the same number of females and males. FGF-2 (250 ng per animal) was administered s.c. twice daily, 3 days per week, until animals were used for immunohistochemistry or survival studies starting at 59 days of age. The BrdUrd ϩ counts and survival studies were carried out in a double blind manner.
Behavorial Analysis. Disease progression and survival status were monitored daily; the first day on which limb tremors were detected was designated the day of disease onset. Rotarod performance (accelerating regime) and lifespan were analyzed as described (17) .
Statistical Analysis. Statistical comparisons of rotarod, weight data, and histology data are compared by ANOVA. Survival data were analyzed by using Kaplan-Meier survival curves (n ϭ 10 per treatment group).
BrdUrd Administration. FGF-2 and vehicle was administered for three weeks before BrdUrd treatment starting at 59 days. BrdUrd (Sigma) was dissolved in saline and given as two i.p. doses of 50 mg͞kg each, spaced 8 h apart per day, for 3 days, and then mice were killed 24 h or 7 days later.
Results
Basal and FGF-2-Stimulated Neurogenesis Is Increased in Subventricular Zone (SVZ) of HD Transgenic R6͞2 Mice. Growth factors can stimulate neurogenesis in some settings, but whether they can do so in genetic HD mouse models is not known. Compared to agematched controls, brain from HD patients expresses increased levels of proliferating cell nuclear antigen, a mitotic marker protein (18) , and Htt itself may be required for neurogenesis (19) . To measure basal and FGF-2-stimulated neurogenesis, vehicle or FGF-2 was injected s.c. in 8-week-old HD transgenic R6͞2 mice and wild-type littermate controls for 3 weeks. BrdUrd, used to detect proliferating cells, was injected i.p. for 3 days, and animals were killed 24 h later for BrdUrd immunohistochemistry (Fig. 1a) . Neurogenesis was measured by counting BrdUrd-labeled cells in the two principal neuroproliferative regions of the adult rodent brain: the SVZ and the subgranular zone of the hippocampal dentate gyrus (DG). Like HD patients, untreated HD transgenic R6͞2 mice showed a statistically significant increase in the number of proliferating cells in the SVZ compared to controls, but the magnitude of increase was modest ( Fig. 1b ; ‫,ء‬ P Ͻ 0.05). However, FGF-2 increased BrdUrd labeling in SVZ of HD transgenic R6͞2 mice by Ϸ150%, whereas in control mice the magnitude of increase was only Ϸ30% (Fig. 1 a and b) . In contrast to SVZ, there was no increase in BrdUrd labeling in DG (data not shown) upon FGF-2 treatment in control and HD transgenic R6͞2 mice. Untreated 8-week-old HD transgenic R6͞2 mice and wild-type littermate controls had similar BrdUrd labeling in the DG as has been reported.
Staining for doublecortin (DCX), a marker for newborn and migrating neurons, was also increased in the SVZ of the HD transgenic R6͞2 mice (198% Ϯ 20% compared to control), suggesting migration of these cells from the SVZ into affected areas of the brain ( Fig. 1 c and d) in the presence of FGF-2. As observed in young adult mice (20) , FGF-2 did not increase proliferating cells in the hippocampus (data not shown). These results demonstrate that neurogenesis is increased in SVZ of HD transgenic R6͞2 mice, and that FGF-2 stimulates neurogenesis to a greater extent in these mice than in controls.
New Neurons in FGF-2-Treated HD Transgenic R6͞2 Mice Express
Phenotypic Features of Medium Spiny Neurons. Virally induced expression of brain-derived neurotrophic factor (BDNF) together with noggin, which inhibits glial differentiation, can stimulate the production of striatal neurons expressing markers of medium spiny neurons (the principal cell type lost in HD), including calbindin, glutamic acid decarboxylase (GAD67), and DARPP-32, a dopamine-regulated phosphoprotein (21) . To determine whether FGF-2 has a similar effect, we doublelabeled brain sections taken from HD transgenic R6͞2 mice treated with FGF-2 and killed at 11 weeks, with antibodies against DCX and DARPP-32 ( Fig. 2a) . Cells migrating into the striatum expressed DARPP-32 ( Fig. 2a) , suggesting maturation along a lineage appropriate for medium spiny neurons. In cerebral cortex, some DCX-expressing cells also expressed the neuronal marker NeuN, consistent with continuing differentiation toward a mature neuronal phenotype (Fig. 2b) .
Newly Generated Neurons Develop Projections to the Globus Pallidus.
Next, we tested whether the new neurons in HD transgenic R6͞2 mice extend processes to their normal target, the globus pallidus. To address this question, we injected the retrograde tracer Alexa Fluor 488 into the globus pallidus of HD transgenic R6͞2 mice treated with FGF-2 ( Fig. 2c Left) and given BrdUrd. One week after FGF-2 treatment and 72 h after injection of the tracer, the mice were killed, and striata were examined for the presence of DCX, NeuN, Alexa Fluor 488, and BrdUrd. The coexpression of DCX, NeuN, and Alexa Fluor 488 (Fig. 2d) , and of BrdUrd with Alexa Fluor 488 (Fig. 2e Left), indicates that newly produced striatal neurons form projections to globus pallidus. DARPP-32, a marker of mature striatal neurons, was also expressed in BrdUrd-labeled striatal cells (Fig. 2e Right) . FGF-2 treatment appears to be responsible for the presence of newborn neurons in the striatum of HD transgenic R6͞2 mice, because no DCX͞BrdUrd immunopositive striatal cells were found in mice given PBS (data not shown).
FGF-2 Treatment Ameliorates Motor Symptoms and Increases Lifespan
in HD Transgenic R6͞2 Mice. To evaluate the functional consequences of FGF-2 treatment, we measured lifespan and motor function in HD transgenic R6͞2 mice, as described (22) . FGF-2 or PBS was administered by s.c. injection twice daily for 3 days per week, starting at 59 days of age (Fig. 3a) . The rotarod latency and weight of FGF-2-treated and untreated mice were the same before treatment, and each treatment group had the same composition of females and males. FGF-2 delayed the onset of mortality in HD transgenic R6͞2 mice from 84 to 100 days, the average survival from 102 to 123 days, and the maximum survival from 118 to 145 days (P Ͻ 0.05). FGF-2 also reduced tremor (data not shown) and improved rotarod performance measured at 11 and 13 weeks of age ( Fig. 3b , P Ͻ 0.01). Finally, FGF-2 treatment produced a modest decrement in weight loss in HD transgenic R6͞2 mice, which reached statistical significance at 13 weeks of age, when mean weights were 17.6 Ϯ 1.2 g for FGF-2-treated and 15.4 Ϯ 0.8 g for PBS-treated mice (P Ͻ 0.05).
FGF-2 Is Neuroprotective in Cell Culture Models of HD.
Growth factors such as BDNF, ciliary neurotrophic factor (CNTF), and IGF-1 inhibit mutant Htt-induced cell death in primary striatal cultures (23) or toxin-induced HD mouse models (24), but FGF-2 has not been evaluated in genetic models of HD. To test whether FGF-2 is neuroprotective in vitro, we used immortalized striatal wild-type STHtt Q7/Q7 and mutant STHtt Q111/Q111 cells derived from HD knock-in mice expressing Htt with expanded, 111-polyglutamine repeats (25) . Withdrawal of serum from STHtt Q111/Q111 cell cultures caused death of 44% of cells after 24 h (Fig. 4a ). This cell death had features of apoptosis, including nuclear fragmentation and activation of caspase-3-like activity (data not shown). Treatment of STHtt Q7/Q7 and mutant STHtt Q111/Q111 cells with FGF-2 (10 ng͞ml) significantly increased cell survival (Fig. 4a) . In contrast, FGF-2 did not increase cell proliferation, as measured by cell number and BrdUrd incorporation (data not shown).
Next, we evaluated whether cell death induced by expression of mutant Htt (full-length Htt or N-terminal polyQ Htt fragments) in primary striatal cultures was rescued by FGF-2 treatment. Using GFP as a positive control, we found we could transfect primary striatal neurons by electroporation with Ͼ50% transfection efficiency (Fig. 4b) . Both full-length Htt138Q-GFP and an N-terminal fragment [Htt147Q(1-111)] produced cell death, affecting 38% and 48% of cells, respectively, by 48 h. Treatment with FGF-2 (10 ng͞ml) resulted in a significant decrease in mutant Htt-induced neuronal death (Fig. 4c) . Again, FGF-2 did not increase cell proliferation as measured by cell number and BrdUrd incorporation (data not shown).
The mechanisms by which FGF-2 stimulates neurogenesis and affords neuroprotection are not known. Because BDNF stimulates striatal neurogenesis (21) and may be depleted in HD striatum (26), we evaluated whether FGF-2 alters BDNF expression in HD transgenic R6͞2 mouse striatum. Western blot analysis of striatal lysates derived from FGF-2-treated HD transgenic R6͞2 and control mice (Fig. 4d) showed no FGF-2-induced increase in the expression of either BDNF or CNTF, another trophic factor that is protective in some models of HD (27) .
FGF-2 Reduces Aggregate Formation and Corrects Signaling Defects in
HD Transgenic R6͞2 Mice. Because alterations in cellular signaling pathways and the hallmark formation of nuclear and cytoplasmic aggregates are well characterized in HD transgenic R6͞2 mice, we evaluated whether FGF-2 treatment corrected any of these cellular changes.
There is an early and dramatic increase in Htt-immunoreactive intraneuronal aggregates in R6͞2 mice. Treatment with FGF-2 resulted in a significant reduction in Htt-positive striatal, cortical, nuclear, and perinuclear aggregates, detected by antibodies against ubiquitin-positive nuclear inclusions (Fig. 5a ) or against the polyglutamine tract of Htt (data not shown), at 11 weeks of age. Quantification of the ubiquitin positive nuclear inclusions demonstrated FGF-2 treatment reduced inclusions by 17% in the striatum (74 Ϯ 4% to 57 Ϯ 4%) and 16% in the cortex (82 Ϯ 4% to 66 Ϯ 1%).
CB1 cannabinoid receptors are down-regulated at the mRNA and protein levels in postmortem HD brain tissue and HD transgenic R6͞2 mice (28, 29) . CB1 receptors have been implicated in FGF-2-induced axonal growth (30) , and also regulate adult neurogenesis (31) . Moreover, cannabinoids are neuroprotective in a variety of cerebral injury models. Therefore, we evaluated whether FGF-2 treatment modified expression of CB1 receptors in HD transgenic R6͞2 mouse striatum. CB1 receptor levels were reduced significantly in the striatum of HD transgenic R6͞2 mice (Fig. 5b) , but FGF-2 treatment restored CB1 receptor expression (Fig. 5b) .
The mutation in HD transgenic R6͞2 mice also downregulates the dopamine-and cAMP-regulated 32-kDa phosphoprotein, DARPP-32 (32) . DARPP-32 is normally enriched in prefrontal cortex and striatum (32) , where it participates in dopamine and serotonin signaling. We found that DARPP-32 levels were reduced by 50% in the striatum of HD transgenic R6͞2 mice (Fig. 5c ). Western blotting (data not shown) and immunostaining also showed that FGF-2 increased DARPP-32 expression in 11-week-old HD transgenic R6͞2 mice (Fig. 5c) .
Discussion
The major findings we report are that FGF-2 stimulates neurogenesis, provides neuroprotection, and extends lifespan in a transgenic mouse model of HD. Neurogenesis, detected by BrdUrd labeling and DCX expression, was increased under basal conditions, and stimulated to a greater extent by FGF-2, in SVZ but not DG of HD transgenic R6͞2 mice. The increase in neurogenesis was associated with migration of nascent neurons into the affected striatum, where they assumed phenotypic features of medium spiny neurons, the principal striatal cell type lost in HD, and extended processes to the globus pallidus, where medium spiny neurons normally project. Neuroprotection was observed both in vitro and in vivo, and was manifested by reductions in neuronal death and protein aggregate formation, restoration toward normal of CB1 cannabinoid receptor and DARPP-32 protein expression, improved neurological function and prolonged survival. Whether neurogenesis, direct neuroprotection, or both contribute to the improvement in neurological function and longevity that we observed cannot be resolved based on the present data. FGF-2 may also have peripheral (nonbrain) effects that contribute to longevity. However, the effect of FGF-2 in HD transgenic R6͞2 mice raises the possibility that FGF-2 or a drug that recapitulates one or more of its effects may provide a prototype for the treatment of HD.
Despite recent advances in understanding the molecular pathogenesis of HD, clinical measures to slow or arrest disease progression are lacking. However, growth factors have received considerable attention in preclinical studies, and several, including nerve growth factor, BDNF, neurotrophins 3 and 4, glial cell-derived neurotrophic factor, neurturin, and CNTF, have shown some benefit in excitotoxic models of HD when administered directly or by gene or cell therapy (reviewed in ref. 27 ). Genetic models of HD have been studied less extensively in this regard, but BDNF expression is decreased in transgenic murine (26) and human (33) HD, and both BDNF and CNTF rescue cultured striatal neurons from death induced by transfection with mutant Htt. FGF-2 treatment in our studies did not alter BDNF levels in the striatum, suggesting that FGF-2 may promote neurogenesis and survival independent of BDNF levels. Prolonged survival has been reported in HD transgenic mice treated with a dominant-negative inhibitor of caspase-1, creatine, minocycline, dichloroacetate, ␣-lipoic acid, cystamine, coezyme Q10, remacemide, the antioxidant BN82451, histone deacetylase inhibitors, rapamycin, or the disaccharide trehalose (reviewed in ref. 34) . In these studies, the increase in mean survival has ranged from 10 to 20%. The mechanisms through which some of these treatments may operate have been inferred from their actions in other systems, but in other cases are unclear. Additional measures that prolong survival in HD transgenic mice include environmental enrichment, the antiexcitotoxin riluzole, and the antidepressant paroxetine, which also have in common the ability to stimulate neurogenesis (reviewed in ref. 34) , although this has not been shown to be the basis for their protective effect in HD.
FGF-2 is neuroprotective in a variety of neurological disease models (reviewed in ref. 35) , including global and focal cerebral ischemia, kainate-induced seizures, and MPTP-mediated parkinsonism. FGF-2 is expressed in substantia nigra, striatum, and globus pallidus of human brain, and FGF receptor expression is increased in HD (36) . In the quinolinic acid model of HD in rats, FGF-2 attenuates changes in cytochrome c oxidase (37) and nitric oxide synthase (24) activity, but there is little other prior evidence to connect FGF-2 with HD. The mechanisms through which FGF-2 produced neuroprotection in our HD transgenic R6͞2 mice may relate to the Akt signaling pathway. FGF-2 activates a range of signal transduction pathways (reviewed in ref. 38) , among which the phosphatidylinositol 3Ј-kinase͞Akt pathway may be especially prominent in promoting cell survival. Notably, Akt signaling has also been implicated in the protective effect of IGF-1 in cultured cells expressing mutant Htt (23) .
The ability of FGF-2 to stimulate neurogenesis in the adult brain is well established. FGF-2 increases the proliferation of neuronal precursors in vitro (39) , and intraventricular infusion of FGF-2 enhances the proliferation and migration of neuronal precursors in the SVZ (40) . Moreover, injury-induced neurogenesis is impaired in FGF-2 knockout mice, and is restored by replacement of FGF-2 using a herpes virus amplicon vector (10). As mentioned above in connection with FGF-2-mediated neuroprotection, the molecular basis for FGF-2-induced neurogenesis remains speculative, although cytoproliferative actions of FGF-2 in other systems have been ascribed to activation of mitogen-activated protein kinase͞extracellular signal-regulated kinase (MEK͞ERK) pathways (38) , and MEK͞ERK signaling has also been implicated in neurogenesis induced by NT-3 and BDNF (41) .
The increased neurogenesis that we observed in HD transgenic R6͞2 mice represents another illustration of the emerging theme that neurogenesis is stimulated in neurological diseases, possibly as an adaptive response directed toward neuronal replacement. Examples include HD (18) and Alzheimer's disease (AD) (42) in humans, as well as animal models of Parkinson's disease (43) , global (44) and focal (45) cerebral ischemia, and epilepsy (46) . Injury-induced neurogenesis shows similarities and differences across disease models, but the examples cited above demonstrate that it can be precipitated by either an acute or chronic and by focal or diffuse brain pathology. There appears to be some degree of regional specificity in the propensity of brain lesions to evoke neurproliferative responses in DG or SVZ. Thus, we observed increased BrdUrd labeling in the juxtastriatal SVZ but not in the DG of our HD transgenic R6͞2 mice, whereas neuronal precursors in DG appear to be mobilized preferentially in disorders that prominently affect the hippocampus, such as global cerebral ischemia (44) and AD (42) . Where injury occurs at a distance from the brain's principal neuroproliferative zones, as best exemplified in focal ischemia, but also true for animal models of HD and AD, newborn neurons migrate from their sites of origin into affected brain areas. In ischemia affecting the striatum (47) and in HD transgenic R6͞2 mice, new neurons migrating into the striatum differentiate toward a phenotype resembling that of the dead or injured cells. Whether these neurons integrate into the surviving brain circuitry and function normally is still unknown, notwithstand-ing that in our HD transgenic R6͞2 mice, they extend projections to anatomically appropriate targets. The contribution of neurogenesis to functional recovery from brain injury is difficult to ascertain because, as in the present study, treatments that stimulate neurogenesis may have additional, potentially beneficial effects on cell function. However, one recent report showed that blocking neurogenesis by cerebral x-irradiation in gerbils impaired recovery from global cerebral ischemia (48) , suggesting that neurogenesis contributes to recovery.
Our findings leave several questions unanswered regarding a possible role for measures that stimulate FGF-2 signaling in the therapeutic approach to HD. These include whether the beneficial effect of FGF-2 might be optimized by, for example, earlier onset of administration, alterations in dosage or route of delivery, or combining FGF-2 with one or more of the numerous growth factors or drugs (discussed above) that yield benefit in animal models of HD, enhance neurogenesis, or both. Other, more fundamental, questions relate to the molecular mechanisms through which FGF-2 modifies the pathophysiology of HD. For example, how does FGF-2 prevent or clear abnormal protein aggregates, and what is the relationship between reduction of protein aggregates and improved neuronal function? It may not be overly optimistic to speculate that new insights into HD might emerge from pursuing these lines of inquiry.
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